Merck

(IN BRIEF) DHL Group has appointed Maike Asmussen as Executive Vice President for Corporate Public Affairs, effective January 1, 2026. She joins from Merck, where she was Chief Political Officer, and brings over two decades of political and advocacy experience, … Read the full press release →

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu plus pertuzumab has been accepted for Priority Review by the FDA for the first-line treatment of HER2-positive metastatic breast cancer. The application is supported by data from the … Read the full press release →

(IN BRIEF) Merck and Siemens have signed a new Memorandum of Understanding that expands their collaboration in life sciences and focuses on accelerating digital transformation across drug discovery, development, and manufacturing. The partnership integrates Merck’s life science SaaS tools and … Read the full press release →

(IN BRIEF) Merck has officially opened its first fully climate-neutral manufacturing facility in Cork, Ireland, with a €150 million investment that will create more than 200 jobs by 2028. The 3,000-square-meter site will produce advanced filtration devices essential for the … Read the full press release →

(IN BRIEF) Merck and mantro GmbH have established EdiMembre, Inc., a Massachusetts-based Deep Tech spin-out dedicated to advancing the alternative protein sector through Merck’s edible membrane technology. Designed to enable scalable production of structured cultivated meat and plant-based products, the … Read the full press release →

(IN BRIEF) The FDA has accepted AstraZeneca’s sBLA for Imfinzi as a perioperative immunotherapy regimen in resectable early‑stage and locally advanced gastric and GEJ cancers, granting Priority Review with a decision expected in Q4 2025. The application leverages MATTERHORN Phase III data … Read the full press release →

(IN BRIEF) Merck brought together top executives from Merck, Siemens, Intel, TRUMPF, and ZEISS in Darmstadt to highlight Europe’s critical contributions to the global semiconductor industry. With leading-edge capabilities in materials, lasers, optics, electronics, chip‑design software, and automation, these companies … Read the full press release →

(IN BRIEF) Merck has awarded its 2025 North American Advance Biotech Grant to Neoclease, a Boston-based startup developing AI-designed gene-editing therapies for Parkinson’s disease and other monogenic disorders. Neoclease will benefit from Merck’s technologies, contract testing, regulatory guidance, and hands-on … Read the full press release →

(IN BRIEF) Merck has entered into a definitive agreement to acquire SpringWorks Therapeutics for approximately $3.9 billion. This acquisition will significantly enhance Merck’s rare tumor portfolio, adding first-in-class therapies for desmoid tumors and NF1-PN. The deal aligns with Merck’s strategy … Read the full press release →

(IN BRIEF) The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherapy significantly improves event-free survival in patients with resectable gastric and gastroesophageal junction cancers compared to standard chemotherapy alone. Interim findings … Read the full press release →

(IN BRIEF) STMicroelectronics has signed its first physical Power Purchase Agreement (PPA) with TotalEnergies to secure renewable energy for its operations in France. The 15-year contract will deliver 1.5 TWh of clean power from two new wind and solar farms, … Read the full press release →